Evidence map›Paper›PMID 30985904›Full record

ArticleHuman molecular genetics2019

Rare variants in MYH15 modify amyotrophic lateral sclerosis risk.

Hyerim Kim, Junghwa Lim, Han Bao, Bin Jiao, Se Min Canon, Michael P Epstein, Keqin Xu, Jie Jiang, Janani Parameswaran, Yingjie Li and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Hyerim KimDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
Junghwa LimDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
Han BaoDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
Bin JiaoDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
Se Min CanonDepartment of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
Michael P EpsteinDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
Keqin XuDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
Jie JiangDepartment of Cell Biology, Emory University and Emory University School of Medicine, Atlanta, GA, USA.
Janani ParameswaranDepartment of Cell Biology, Emory University and Emory University School of Medicine, Atlanta, GA, USA.
Yingjie LiDepartment of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
Kenneth H MobergDepartment of Cell Biology, Emory University and Emory University School of Medicine, Atlanta, GA, USA.
John E LandersDepartment of Neurology, University of Massachusetts Medical School, Worcester, MA, USA.
Christina FournierDepartment of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
Emily G AllenDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
Jonathan D GlassDepartment of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
Thomas S WingoDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
Peng JinDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
Emory University · USAtlanta VA Medical Center · USUniversity of Massachusetts Chan Medical School · US

Funding

The Emory Alzheimer's Disease CenterP50AG025688 · NIA · EMORY UNIVERSITY · PI LEVEY, ALLAN I · 2005 to 2019
$25.7M
Molecular Basis of rCGG-Mediated NeurodegenerationR01NS051630 · NINDS · EMORY UNIVERSITY · PI NELSON, DAVID LOREN · 2006 to 2023
$9.8M
Recruitment CoreU54NS091859 · NINDS · EMORY UNIVERSITY · PI WARREN, STEPHEN T. · 2014 to 2019
$9.1M
Identification of genes causative for familial ALS gene using exome sequencingR01NS073873 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LANDERS, JOHN E · 2011 to 2019
$4.6M
Translational models of neurodevelopmental epigenetics and disease using human iPSCsP01NS097206 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI SONG, HONGJUN · 2016 to 2020
$4.3M
Understanding the molecular mechanisms of Depression and Psychological Well-being in Alzheimer's diseaseR01AG056533 · NIA · EMORY UNIVERSITY · PI WINGO, ALIZA PHAM, WINGO, THOMAS SPURGEON · 2017 to 2021
$3.9M
Computational Prediction and Functional Validation of Novel Epigenetic Risk Loci in Alzheimer's DiseaseR56AG062256 · NIA · EMORY UNIVERSITY · PI JIN, PENG, QIN, ZHAOHUI · 2018 to 2018
$788k
Computational Prediction and Functional Validation of Novel Risk Loci of Alzheimer's DiseaseR56AG060757 · NIA · EMORY UNIVERSITY · PI JIN, PENG, QIN, ZHAOHUI · 2018 to 2018
$788k
Identification and Characterization of ALS/FTD Associated Variants Using Whole Genome SequencingR56NS073873 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LANDERS, JOHN E · 2020 to 2020
$586k
A Genetic Study of a Large Pedigree with Late-onset Alzheimer's DiseaseIK2BX001820 · VA · VETERANS HEALTH ADMINISTRATION · PI WINGO, THOMAS SPURGEON · 2014 to 2018
–
BLRD VA IK2 BX001820NIA NIH HHS P50 AG025688NIA NIH HHS R01 AG056533NINDS NIH HHS P01 NS097206NINDS NIH HHS R01 NS051630NINDS NIH HHS R01 NS073873NINDS NIH HHS R56 NS073873NINDS NIH HHS U54 NS091859
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder characterized by progressive muscular atrophy and respiratory failure. The G4C2 repeat expansion in the C9orf72 gene is the most prevalent genetic risk for ALS. Mutation carriers (C9ALS) display variability in phenotypes such as age-at-onset and duration, suggesting the existence of additional genetic factors. Here we introduce a three-step gene discovery strategy to identify genetic factors modifying the risk of both C9ALS and sporadic ALS (sALS) using limited samples. We first identified 135 candidate genetic modifiers of C9ALS using whole-genome sequencing (WGS) of extreme C9ALS cases diagnosed ~30 years apart. We then performed an unbiased genetic screen using a Drosophila model of the G4C2 repeat expansion with the genes identified from WGS analysis. This genetic screen identified the novel genetic interaction between G4C2 repeat-associated toxicity and 18 genetic factors, suggesting their potential association with C9ALS risk. We went on to test if 14 out of the 18 genes, those which were not known to be risk factors for ALS previously, are also associated with ALS risk in sALS cases. Gene-based-statistical analyses of targeted resequencing and WGS were performed. These analyses together reveal that rare variants in MYH15 represent a likely genetic risk factor for ALS. Furthermore, we show that MYH15 could modulate the toxicity of dipeptides produced from expanded G4C2 repeat. Our study presented here demonstrates the power of combining WGS with fly genetics to facilitate the discovery of fundamental genetic components of complex traits with a limited number of samples.

Indexed as

DNA Repeat ExpansionAdultAgedAmyotrophic Lateral SclerosisAnimalsAnimals, Genetically ModifiedC9orf72 ProteinDipeptidesDisease Models, AnimalDrosophilaDrosophila ProteinsFemaleHumansMaleMicrofilament ProteinsMutationC9orf72 ProteinDipeptidesDrosophila ProteinsMicrofilament ProteinsMYH15 protein, humanMyosin Heavy ChainsSALS protein, Drosophila

Identifiers

PMID30985904
PMCPMC6606848
OpenAlexW2930937011

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.